간암 진단 시장 - 전략적 인사이트와 예측(2026-2035년)

The Liver Cancer Diagnostics Market is set to reach USD 11.85 billion in 2035, growing at a CAGR of 9.8 % from USD 5.11 billion in 2026.

The liver cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward early detection, precision oncology, and non-invasive diagnostic technologies. The market's evolution is characterized by the growing recognition that timely and accurate diagnosis is essential for improving survival outcomes, as liver cancer is frequently diagnosed at advanced stages when therapeutic options are limited. The convergence of advanced imaging modalities, molecular diagnostics, liquid biopsy technologies, and artificial intelligence is enabling faster, more sensitive, and increasingly accessible liver cancer detection and characterization. Healthcare systems worldwide are expanding surveillance programs among high-risk populations as the global burden of hepatocellular carcinoma continues to rise due to chronic hepatitis B and C infections, non-alcoholic fatty liver disease, cirrhosis, and metabolic disorders. The market is witnessing significant investment in multi-biomarker panels, next-generation sequencing, and companion diagnostics, positioning liver cancer diagnostics as a critical component of gastrointestinal oncology and precision medicine.

Market Drivers

• The increasing prevalence of hepatocellular carcinoma and chronic liver diseases represents the primary driver for the liver cancer diagnostics market. Rising disease burden creates sustained demand for diagnostic testing across screening, surveillance, early detection, diagnosis, treatment selection, and disease monitoring applications. Healthcare systems are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in liver cancer diagnostic utilization. Rising hepatitis B and hepatitis C infections globally are further accelerating market growth through increased surveillance and diagnostic testing. Chronic viral hepatitis remains a major risk factor for hepatocellular carcinoma, creating sustained demand for liver cancer screening among infected populations. Healthcare providers are expanding surveillance programs for high-risk patients to enable earlier detection. Diagnostic manufacturers are developing specialized testing solutions to support hepatitis-related liver cancer screening. The growing adoption of precision oncology and companion diagnostics is driving demand for molecular profiling and genomic testing. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for advanced diagnostic technologies. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized molecular and genomic testing solutions to support precision oncology applications. The expansion of cancer screening and surveillance programs is increasing demand for early detection technologies. Healthcare systems are implementing surveillance programs for high-risk populations to enable earlier diagnosis and improve outcomes. This creates sustained demand for sensitive imaging modalities and biomarker testing.

Market Restraints

• High costs associated with advanced molecular diagnostic testing limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited access to specialized diagnostics in low-income regions restricts patient access and adoption. The shortage of specialized laboratories and trained personnel limits the scalability of molecular diagnostics. Stringent regulatory approval requirements increase development timelines and costs for manufacturers. The rigorous evidence requirements for new diagnostic products create barriers to market entry. Variability in biomarker sensitivity and specificity reduces clinical confidence and adoption. Reimbursement limitations for emerging diagnostic technologies restrict patient access and adoption.

Technology and Modality Insights

• The technology landscape is characterized by the growing importance of molecular diagnostics, liquid biopsy, and AI-enabled imaging platforms. Imaging diagnostics continue to dominate the market as ultrasound, CT, and MRI remain the primary tools for liver lesion detection and disease staging. Laboratory diagnostics and histopathology remain essential for diagnosis confirmation. Molecular diagnostics are experiencing the fastest growth due to increasing adoption of genomic profiling, liquid biopsy, and precision oncology. The segment analysis reveals that immunohistochemistry remains widely utilized for tumor characterization and pathology evaluation. PCR-based testing continues supporting biomarker detection and viral diagnostics. NGS is the fastest-growing technology owing to increasing use in precision oncology and targeted therapy selection. FISH and immunoassays continue supporting specialized biomarker evaluation and companion diagnostic applications. AFP remains the most widely utilized biomarker for liver cancer screening and monitoring. AFP-L3 and DCP/PIVKA-II are increasingly adopted to improve diagnostic sensitivity and specificity. Glypican-3 and emerging multi-biomarker panels continue gaining clinical importance. Screening and surveillance represent critical applications because of the importance of early detection in high-risk populations. Hospitals represent the leading end-user segment, with diagnostic laboratories and cancer research centers expanding testing capabilities. The integration of AI is becoming increasingly important as AI-assisted imaging improves lesion detection and characterization.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized molecular, imaging, and precision oncology providers. Roche develops comprehensive liver cancer diagnostic solutions including molecular diagnostics, tissue diagnostics, companion diagnostics, and immunohistochemistry platforms supporting precision oncology. Abbott provides immunoassays, clinical chemistry platforms, molecular diagnostics, and biomarker testing solutions supporting liver disease and oncology diagnostics. Siemens Healthineers offers advanced imaging systems, laboratory diagnostics, immunoassays, and digital healthcare technologies supporting liver cancer diagnosis. Thermo Fisher Scientific develops molecular diagnostic assays, PCR technologies, sequencing solutions, and precision oncology products supporting liver cancer diagnostics. Danaher provides molecular diagnostics, genomics technologies, life science solutions, and laboratory automation supporting oncology biomarker testing. Agilent specializes in pathology solutions, immunohistochemistry assays, companion diagnostics, and genomic technologies supporting liver cancer diagnosis. QIAGEN develops molecular diagnostic assays, sample preparation technologies, PCR kits, and companion diagnostics supporting precision oncology. Illumina is a global leader in NGS platforms enabling genomic profiling, biomarker discovery, and precision oncology applications. Companies are pursuing product portfolio expansion through innovation in liquid biopsy, multi-biomarker panels, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with advanced multi-cancer genomic testing capabilities. Roche introduced enhanced companion diagnostic solutions supporting precision oncology for liver cancer. Illumina expanded oncology sequencing applications for comprehensive tumor genomic profiling. Thermo Fisher Scientific launched updated NGS workflows for solid tumor diagnostics. Agilent Technologies expanded immunohistochemistry assay offerings supporting liver cancer pathology.

Short Conclusion

• The liver cancer diagnostics market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated non-invasive and molecular strategies represents a fundamental shift in gastrointestinal oncology. While challenges related to high costs, access limitations, and regulatory requirements persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with liver cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Liver Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Disease Evolution and Diagnostic Landscape
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Prevalence Analysis
• 3.8 Diagnosed Patient Population Analysis
• 3.9 Liver Cancer Diagnostic Testing Volume Analysis
• 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Liquid Biopsy for Liver Cancer
• 6.4 Artificial Intelligence in Liver Cancer Diagnostics
• 6.5 Companion Diagnostics Development
• 6.6 Biomarker Discovery
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Liver Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Diagnostic Modality
  • 8.1.1 Imaging Diagnostics
  • 8.1.2 Laboratory Diagnostics
  • 8.1.3 Histopathology
  • 8.1.4 Molecular Diagnostics
• 8.2 Analysis by Technology
  • 8.2.1 Immunohistochemistry (IHC)
  • 8.2.2 Polymerase Chain Reaction (PCR)
  • 8.2.3 Next-Generation Sequencing (NGS)
  • 8.2.4 Fluorescence In Situ Hybridization (FISH)
  • 8.2.5 Immunoassays
• 8.3 Analysis by Biomarker
  • 8.3.1 Alpha-Fetoprotein (AFP)
  • 8.3.2 AFP-L3
  • 8.3.3 Des-Gamma-Carboxy Prothrombin (DCP/PIVKA-II)
  • 8.3.4 Glypican-3 (GPC3)
  • 8.3.5 Other Biomarkers
• 8.4 Analysis by Clinical Application
  • 8.4.1 Screening & Surveillance
  • 8.4.2 Early Detection
  • 8.4.3 Diagnosis
  • 8.4.4 Treatment Selection
  • 8.4.5 Disease Monitoring

9. Global Liver Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software
• 9.2 By Technology
  • 9.2.1 Immunohistochemistry (IHC)
  • 9.2.2 Polymerase Chain Reaction (PCR)
  • 9.2.3 Next-Generation Sequencing (NGS)
  • 9.2.4 Fluorescence In Situ Hybridization (FISH)
  • 9.2.5 Immunoassays
  • 9.2.6 Other Technologies
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Academic & Research Institutes
  • 9.3.4 Cancer Research Centers

10. Global Liver Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Liver Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Abbott Laboratories
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Siemens Healthineers AG
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 Thermo Fisher Scientific Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 Danaher Corporation
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 Agilent Technologies, Inc.
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 QIAGEN N.V.
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 bioMerieux
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Bio-Rad Laboratories, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 Illumina, Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 Guardant Health, Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Exact Sciences Corporation
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 Sysmex Corporation
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 Fujifilm Holdings Corporation
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 Leica Biosystems
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Liver Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Imaging Diagnostics
• 14.2 Immunohistochemistry (IHC)-Based Diagnostics
• 14.3 Molecular Diagnostic Tests
• 14.4 Alpha-Fetoprotein (AFP) Tests
• 14.5 Liquid Biopsy Tests
• 14.6 Next-Generation Sequencing (NGS)-Based Tests
• 14.7 Companion Diagnostic Tests

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends